Database

Startups

Main Industry
Biotechnology
Main Product/Service
1. HANSIZHUANG (serplulimab)
2. HLX04 (bevacizumab)
3. HLX10 (serplulimab, HANSIZHUANG)
4. HLX53
5. Manufacturing and Quality Management
6. Clinical Trials
Founded Year
2010
Unified Business No.
53183491
Status
Closed
Number of Employees
0
Total Paid-in Capital
780,511,490 (NT$)
Location of Company
Taiwan , Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
Shanghai Henlius Biotech provides clinical-stage biopharmaceutical services. The company focuses on the development, production and commercialization of mAb biosimilar drugs, bio-betters, and novel mAbs using cutting-edge technology.

The company is a joi



More ↓

Similar Companies

Rephlmmune Biotechnology Inc.

RephImmune is pioneering a new frontier in cancer immunotherapy with its proprietary platform, Reconstitute-Immunity Antigen-Cell Engager (RACE). This cutting-edge technology is rooted in regeneration biology and is specifically designed to reprogram and

ARCE THERAPEUTICS, INC.

ARD103
ANTI-CLL1 auto-CAR-T
ARD103, our priority product, is an autologous CAR-T cell manufactured by DashCAR® technology with an ultra-fast processing time and stem cell-like phenotypes. ARD103 specifically targeted C-type lectin-like molecule-1 (CLL-1)